Clinical Trial Detail

NCT ID NCT04317534
Title Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Greg Durm, MD
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.